Open AccessSustained acoustic medicine; sonophoresis for nonsteroidal anti-inflammatory drug delivery in arthritis
Author(s) -
Jack A. Masterson,
Brett Kluge,
Aaron Burdette,
George K. Lewis
Publication year - 2020
Publication title -
therapeutic delivery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.619
H-Index - 46
eISSN - 2041-6008
pISSN - 2041-5990
DOI - 10.4155/tde-2020-0009
Subject(s) - diclofenac , transdermal , phonophoresis , nonsteroidal , medicine , drug delivery , drug , penetration (warfare) , pharmacology , arthritis , ultrasound , materials science , nanotechnology , operations research , engineering , radiology
Background: Arthritis pain is primarily managed by nonsteroidal anti-inflammatory drugs (NSAIDs), such as diclofenac. Topical diclofenac gel is limited in efficacy due to its limited penetration through the skin. This study investigates the use of a multihour, wearable, localized, sonophoresis transdermal drug delivery device for the penetration enhancement of diclofenac through the skin. Materials & methods: A commercially available, sustained acoustic medicine (sam ® ) ultrasound device providing 4 h, 1.3 W, 132 mW/cm 2 , 3 MHz ultrasound treatment was evaluated for increasing the drug delivery of diclofenac gel through a human skin model and was compared with standard of care topical control diclofenac gel. Results: Sonophoresis of the diclofenac gel for 4 h increases diclofenac delivery by 3.8× (p < 0.01), and penetration by 32% (p < 0.01). Conclusion: Sustained acoustic medicine can be used as a transdermal drug-delivery device for nonsteroidal anti-inflammatory drugs.